The Clinical Core seeks to improve the diagnosis and management of individuals with Parkinson disease (PD) through its support of the JHU Udall Center and Clinical Project 3. With this funding period request, the Clinical Core will add biofluid ascertainment (blood, urine, and cerebrospinal fluid (CSF)) to its existing 15-year longitudinal study and brain autopsy program. Through the collection of biofluids from individuals who undergo autopsy the Clinical Core is uniquely situated to allow the Clinical Project to identify PD biomarkers. In addition, to ensure that the Clinical Project has sufficient CSF to complete its aims, the Clinical Core will be responsible for obtaining CSF through collaborations with other cohorts both within and outside JHU. The Clinical Core also seeks to fulfill the mission of the JHU Udall Center through its efforts to educate patients, their families, and health care providers regarding the Center's research activities, PD diagnosis and treatment.

Public Health Relevance

The Clinical Core will be a shared resource of the Parkinson's Disease Research Center and will play a central role in our investigations in the pathogenesis of Parkinson's Disease. The Clinical Core will provide vital support to the Clinical Project 3 through its acquisition of cerebrospinal fluid. It will also support the missions of the other cores and projects through its longitudinal investigation and brain autopsy program as well as education initiatives.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-J (07))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Martin, Ian; Kim, Jungwoo Wren; Dawson, Valina L et al. (2014) LRRK2 pathobiology in Parkinson's disease. J Neurochem 131:554-65
Dawson, Ted M; Dawson, Valina L (2014) Parkin plays a role in sporadic Parkinson's disease. Neurodegener Dis 13:69-71
Lee, Yun-Il; Giovinazzo, Daniel; Kang, Ho Chul et al. (2014) Protein microarray characterization of the S-nitrosoproteome. Mol Cell Proteomics 13:63-72
Siuda, Joanna; Jasinska-Myga, Barbara; Boczarska-Jedynak, Magdalena et al. (2014) Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. Parkinsonism Relat Disord 20:1274-8
Fatokun, Amos A; Dawson, Valina L; Dawson, Ted M (2014) Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 171:2000-16
Stafa, Klodjan; Tsika, Elpida; Moser, Roger et al. (2014) Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Hum Mol Genet 23:2055-77
Martin, Ian; Kim, Jungwoo Wren; Lee, Byoung Dae et al. (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell 157:472-85
Tsika, Elpida; Glauser, Liliane; Moser, Roger et al. (2014) Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet 23:4621-38
Pirooznia, Sheila K; Dawson, Valina L; Dawson, Ted M (2014) Motor neuron death in ALS: programmed by astrocytes? Neuron 81:961-3
Lasagna-Reeves, Cristian A; Sengupta, Urmi; Castillo-Carranza, Diana et al. (2014) The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun 2:56

Showing the most recent 10 out of 141 publications